
May 28 (Reuters) - Veru Inc VERU.O:
VERU REPORTS POSITIVE SAFETY RESULTS FROM PHASE 2B QUALITY STUDY: ENOBOSARM ADDED TO SEMAGLUTIDE LED TO GREATER FAT LOSS, PRESERVATION OF MUSCLE, AND FEWER GASTROINTESTINAL SIDE EFFECTS COMPARED TO SEMAGLUTIDE ALONE
VERU INC - TOPLINE DATA FOR PHASE 2B EXTENSION STUDY EXPECTED IN SECOND QUARTER
VERU INC: TRIAL MET ITS PRESPECIFIED PRIMARY ENDPOINT
VERU INC - REQUESTS END OF PHASE 2 MEETING WITH FDA FOR PHASE 3 REGULATORY CLARITY